Pfizer quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	653	603	+8.3%
EBITDA	248	210	+17.9%
EBITDA margin	37.9%	34.8%	+3.1 pts
Profit before tax	277	260	+6.6%
Net profit	204	192	+6.6%
EPS	₹44.69	₹41.91	+6.6%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	653	629	645	642	603	592	538	589	563	547	540	575	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	44.8	40.7	38.2	41.9	67.2	44.6	42.8	43.1	41.8	75.1	35.9	36.1
	698	670	683	684	670	636	581	632	605	622	576	611
	105	83.0	67.8	70.0	88.7	70.6	67.3	76.7	57.7	88.7	77.2	83.8
	183	118	145	221	124	140	105	80.7	188	94.0	149	79.1
	−47.8	19.6	11.8	−63.3	−1.7	−7.7	24.3	53.4	−44.6	6.7	−43.3	41.9
	82.1	77.2	100	94.7	95.8	82.9	96.3	101	91.4	75.1	89.4	89.8
	1.5	2.1	2.0	2.1	3.3	2.7	1.5	2.1	2.1	7.0	2.9	2.7
	14.3	14.8	14.3	14.3	14.4	16.4	14.8	15.0	14.6	13.8	17.6	15.4
	83.4	95.7	91.8	89.8	86.0	79.0	99.2	87.9	93.3	92.8	115	98.0
	421	410	433	429	411	384	408	416	402	378	408	411
	248	236	228	230	210	228	146	189	177	189	153	183
	233	221	214	216	196	211	131	174	163	176	135	167
Profit
	277	260	250	255	260	253	172	215	203	244	168	201
	0.0	9.0	−58.2	0.0	0.0	173	0.0	0.0	0.0	0.0	8.0	0.0
	277	269	192	255	260	426	172	215	203	244	176	201
	70.9	66.6	58.0	65.5	67.4	99.1	50.1	59.9	55.1	49.0	29.2	47.3
	1.3	2.4	−7.9	0.9	0.4	−4.2	−5.3	−3.0	−3.1	16.0	16.8	4.2
	72.2	69.0	50.1	66.4	67.8	94.9	44.8	56.9	51.9	65.0	46.0	51.6
	204	200	142	189	192	331	128	158	151	179	130	149
	204	200	142	189	192	331	128	158	151	179	130	149
	−0.5	3.8	1.9	−0.9	−0.9	2.4	−0.5	−0.5	−0.5	7.9	−0.8	−0.8
	204	204	144	188	191	333	127	158	150	187	129	148
Per share
	₹44.69	₹43.68	₹31.01	₹41.32	₹41.91	₹72.34	₹27.89	₹34.61	₹32.94	₹22.33	₹27.12	₹32.56
	₹44.69	₹43.68	₹31.01	₹0.00	₹41.91	₹72.34	₹27.89	₹0.00	₹32.94	₹22.33	₹27.12	₹32.56
Other comprehensive income — detail
	−0.5	3.8	1.9	−0.9	−0.9	2.4	—	—	—	—	—	—
	−0.7	5.1	—	—	—	—	−0.7	—	−0.7	—	—	—
	−0.2	1.3	−2.5	1.2	1.2	−3.1	—	—	—	—	—	—
	—	—	—	—	—	—	−0.2	0.7	−0.2	−10.6	1.1	1.1
	0.0	0.0	0.6	−0.3	−0.3	0.8	—	—	—	—	—	—
	—	—	—	—	—	—	—	−0.2	0.0	2.7	−0.3	−0.3
Per share — as-filed variants
	₹44.69	₹43.68	₹31.01	₹41.32	₹41.91	₹72.34	₹27.89	₹34.61	₹32.94	₹22.33	₹27.12	₹32.56
	₹44.69	₹43.68	₹31.01	₹0.00	₹41.91	₹72.34	₹27.89	₹0.00	₹32.94	₹22.33	₹27.12	₹32.56
Regulatory disclosures — filed alongside, not part of the P&L
	—	335	—	862	—	361	—	—	—	—	—	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	413	409	420	414	392	389	341	378	362	357	357	370
	63.2%	65.0%	65.2%	64.5%	65.0%	65.8%	63.5%	64.2%	64.3%	65.4%	66.2%	64.4%
Adjusted (ex-exceptional items) — derived
	277	260	250	255	260	253	172	215	203	244	168	201
	0.0	9.0	−58.2	0.0	0.0	173	0.0	0.0	0.0	0.0	8.0	0.0
	204	193	185	189	192	197	128	158	151	179	124	149
	₹44.69	₹42.21	₹40.41	₹41.32	₹41.91	₹42.98	₹27.89	₹34.61	₹32.94	₹22.33	₹25.89	₹32.56

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

PFIZER₹3,734.40

Pfizer Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersGLAXO ABBOTINDIA POLYMED ONESOURCE RAINBOW KIMS JUBLPHARMA VIJAYA

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	575.2	540.0	546.6	562.9	588.6	538.0	591.9	603.1	642.3	645.0	629.2	653.2
Other Income	36.1	35.9	75.1	41.8	43.1	42.8	44.6	67.2	41.9	38.2	40.7	44.8
Total Income	611.3	575.8	621.8	604.7	631.7	580.8	636.5	670.2	684.2	683.2	670.0	698.0
Expenses
+ Cost of Materials Consumed	83.8	77.2	88.7	57.7	76.7	67.3	70.6	88.7	70.0	67.8	83.0	105.0
+ Purchases of Stock-in-Trade	79.1	148.6	94.0	187.6	80.7	105.0	139.5	124.3	221.3	145.2	117.7	182.9
+ Changes in Inventories	41.9	-43.3	6.7	-44.6	53.4	24.3	-7.7	-1.7	-63.3	11.8	19.6	-47.8
+ Employee Benefit Expense	89.8	89.4	75.1	91.4	100.8	96.3	82.9	95.8	94.7	100.3	77.2	82.1
+ Finance Costs	2.7	2.9	7.0	2.1	2.1	1.5	2.7	3.3	2.1	2.0	2.1	1.5
+ Depreciation & Amortisation	15.4	17.6	13.8	14.6	15.0	14.8	16.4	14.4	14.3	14.3	14.8	14.3
+ Other Expenses	98.0	115.5	92.8	93.3	87.9	99.2	79.0	86.0	89.8	91.8	95.7	83.4
Total Expenses	410.8	407.8	377.9	402.1	416.4	408.3	383.5	410.7	428.8	433.1	410.2	421.3
EBITDA	182.6	152.6	189.4	177.5	189.3	146.0	227.5	210.0	229.9	228.2	236.0	247.6
EBIT	167.2	135.0	175.7	162.9	174.3	131.2	211.1	195.6	215.7	213.9	221.2	233.3
Profit
PBT before Exceptional Items	200.5	168.0	243.9	202.6	215.2	172.4	253.0	259.5	255.4	250.2	259.8	276.7
+ Exceptional Items	0.0	8.0	0.0	0.0	0.0	0.0	172.8	0.0	0.0	-58.2	9.0	0.0
Pretax Income	200.5	175.9	243.9	202.6	215.2	172.4	425.8	259.5	255.4	192.0	268.8	276.7
+ Current Tax	47.3	29.2	49.0	55.1	59.9	50.1	99.1	67.4	65.5	58.0	66.6	70.9
+ Deferred Tax	4.2	16.8	16.0	-3.1	-3.0	-5.3	-4.2	0.4	0.9	-7.9	2.4	1.3
Tax Expense	51.6	46.0	65.0	51.9	56.9	44.8	94.9	67.8	66.4	50.1	69.0	72.2
Net Income	149.0	130.0	178.9	150.7	158.4	127.6	330.9	191.8	189.0	141.8	199.8	204.5
+ Net Income — Continuing Ops	149.0	130.0	178.9	150.7	158.4	127.6	330.9	191.8	189.0	141.8	199.8	204.5
+ Other Comprehensive Income	-0.8	-0.8	7.9	-0.5	-0.5	-0.5	2.4	-0.9	-0.9	1.9	3.8	-0.5
Total Comprehensive Income	148.1	129.2	186.8	150.2	157.8	127.1	333.3	190.8	188.1	143.7	203.6	203.9
Per Share
Basic EPS	32.56	27.12	22.33	32.94	34.61	27.89	72.34	41.91	41.32	31.01	43.68	44.69
Diluted EPS	32.56	27.12	22.33	32.94	0.00	27.89	72.34	41.91	0.00	31.01	43.68	44.69
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	2.4	-0.9	-0.9	1.9	3.8	-0.5
+ Items NOT to be Reclassified to P&L	—	—	—	-0.7	—	-0.7	—	—	—	—	5.1	-0.7
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-3.1	1.2	1.2	-2.5	1.3	-0.2
+ Tax on Items NOT to be Reclassified — alt tag	1.1	1.1	-10.6	-0.2	0.7	-0.2	—	—	—	—	—	—
+ Tax on Items to be Reclassified	—	—	—	—	—	—	0.8	-0.3	-0.3	0.6	0.0	0.0
+ Tax on Items to be Reclassified — alt tag	-0.3	-0.3	2.7	0.0	-0.2	—	—	—	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	32.56	27.12	22.33	32.94	34.61	27.89	72.34	41.91	41.32	31.01	43.68	44.69
Diluted EPS — Continuing Operations	32.56	27.12	22.33	32.94	0.00	27.89	72.34	41.91	0.00	31.01	43.68	44.69
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period	—	—	—	—	—	—	361.5	—	861.8	—	334.9	—
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	370.4	357.4	357.3	362.2	377.9	341.4	389.4	391.8	414.4	420.3	408.9	413.1
Gross Margin %	64.40	66.19	65.36	64.34	64.20	63.46	65.79	64.97	64.51	65.15	64.98	63.24
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	200.5	168.0	243.9	202.6	215.2	172.4	253.0	259.5	255.4	250.2	259.8	276.7
− Exceptional Items (reconciliation)	0.0	8.0	0.0	0.0	0.0	0.0	172.8	0.0	0.0	-58.2	9.0	0.0
Net Income Adj (tax-effected)	149.0	124.1	178.9	150.7	158.4	127.6	196.6	191.8	189.0	184.8	193.1	204.5
EPS Adj	32.56	25.89	22.33	32.94	34.61	27.89	42.98	41.91	41.32	40.41	42.21	44.69
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	45.8	45.8	45.8	45.8	45.8	45.8	45.8	45.8	45.8	45.8	45.8	45.8

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Pfizer Q2 FY27 results date

Pfizer (NSE: PFIZER) will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, according to the board-meeting notice it filed on 26 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹204 crore, up 6.6% from ₹192 crore in Q1 FY26 and up 2.3% from ₹200 crore in Q4 FY26. Revenue from operations was ₹653 crore, up 8.3% year on year and up 3.8% from the previous quarter.

Board-meeting notice filed: 26 October 2026
Q2 FY26 results (a year earlier): 12 November 2025
Q1 FY27 results (the latest): 28 July 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 3 November 2026Tuesday · notice filed 26 Oct
Q1 FY27 net profit: ₹204 Cr+6.6% vs Q1 FY26+2.3% vs Q4 FY26
Q1 FY27 revenue: ₹653 Cr+8.3% vs Q1 FY26+3.8% vs Q4 FY26
Q1 FY27 operating margin: 35.7%+3.3 pts vs Q1 FY26+0.6 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹189 CrRevenue ₹642 Cr
Q1 FY27 EPS (basic): ₹44.69

Questions

When will Pfizer announce its Q2 FY27 results?

On 3 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 26 October 2026). Last year it reported Q2 FY26 on 12 November 2025.

What were Pfizer's Q1 FY27 results?

Consolidated net profit was ₹204 crore, up 6.6% from ₹192 crore in Q1 FY26 and up 2.3% from ₹200 crore in Q4 FY26. Revenue from operations was ₹653 crore, up 8.3% year on year and up 3.8% from the previous quarter.

What was Pfizer's net profit in FY26?

Consolidated net profit was ₹722 crore in FY26 (April 2025–March 2026), down 5.9% from ₹768 crore in FY25. It was ₹551 crore in FY24 and ₹624 crore in FY23: up 15.8% over three years, 5.0% a year on average.

What will Pfizer's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹189 crore and revenue from operations ₹642 crore. The latest quarter, Q1 FY27, had a net profit of ₹204 crore and revenue of ₹653 crore.

How has Pfizer's profit changed over the last four quarters?

Net profit by quarter: ₹189 crore in Q2 FY26, ₹142 crore in Q3 FY26, ₹200 crore in Q4 FY26 and ₹204 crore in Q1 FY27. That is ₹735 crore over the four quarters, down 9.1% from ₹809 crore in the four quarters before. Revenue from operations: ₹642 crore, ₹645 crore, ₹629 crore and ₹653 crore.

What was Pfizer's revenue in FY26?

Revenue from operations was ₹2,520 crore in FY26 (April 2025–March 2026), up 10.4% from ₹2,281 crore in FY25. It was ₹2,193 crore in FY24 and ₹2,425 crore in FY23: up 3.9% over three years, 1.3% a year on average.

Where do these Pfizer figures come from?

From Pfizer's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.